Recent Winners


+180%
PLX
Alert Price: $0.36
High Price: $1.01
Results: 180% in 40 Days
+157%
OREX
Alert Price: $1.81
High Price: $4.65
Results: 157% in 36 Days
+133%
CGIX
Alert Price: $1.50
High Price: $3.50
Results: 133% in 85 Days
+91%
GBT
Alert Price: $15.85
High Price: $30
Results: 91% in 41 Days
+90%
LPTH
Alert Price: $1.40
High Price: $2.66
Results: 90% in 69 Days
+87%
ARIA
Alert Price: $12.72
High Price: $23.75
Results: 87% in 20 Days
+72%
TRR
Alert Price: $10.10
High Price: $17.38
Results: 72% in 51 Days
+64%
MBLY
Alert Price: $37.68
High Price: $61.73
Results: 64% in 67 Days
+58%
AAOI
Alert Price: $28.22
High Price: $44.46
Results: 58% in 60 Days
+58%
XGTI
Alert Price: $1.47
High Price: $2.32
Results: 58% in 29 Days
+55%
EXAS
Alert Price: $15.10
High Price: $23.40
Results: 55% in 37 Days
+47%
CPRX
Alert Price: $1.20
High Price: $1.76
Results: 47% in 60 Days
+45%
PTLA
Alert Price: $25.06
High Price: $36.40
Results: 45% in 67 Days
+44%
VRTX
Alert Price: $79.39
High Price: $114.06
Results: 44% in 51 Days
+38%
EDIT
Alert Price: $18.24
High Price: $25.09
Results: 38% in 55 Days
+36%
CYNO
Alert Price: $48.25
High Price: $65.90
Results: 36% in 28 Days
+35%
NKTR
Alert Price: $13.75
High Price: $18.50
Results: 35% in 51 Days
+32%
EBS
Alert Price: $27.22
High Price: $35.88
Results: 32% in 6 Days
+31%
ATVI
Alert Price: $37.05
High Price: $48.42
Results: 31% in 68 Days
+27%
ILMN
Alert Price: $134.56
High Price: $171.52
Results: 27% in 55 Days
+27%
ICHR
Alert Price: $13.40
High Price: $17.04
Results: 27% in 22 Days
+27%
QRVO
Alert Price: $55.67
High Price: $70.64
Results: 27% in 73 Days
+25%
WILN
Alert Price: $1.58
High Price: $1.98
Results: 25% in 72 Days
+25%
BMA
Alert Price: $70.05
High Price: $87.41
Results: 25% in 61 Days
+23%
CNAT
Alert Price: $4.43
High Price: $5.45
Results: 23% in 3 Days
+23%
PEIX
Alert Price: $8.30
High Price: $10.25
Results: 23% in 12 Days
+21%
KATE
Alert Price: $15.40
High Price: $18.67
Results: 21% in 11 Days
+20%
REPH
Alert Price: $6.89
High Price: $8.25
Results: 20% in 11 Days
+20%
GNRT
Alert Price: $4.49
High Price: $5.37
Results: 20% in 62 Days
+20%
SN
Alert Price: $11.24
High Price: $13.46
Results: 20% in 15 Days
+20%
DXCM
Alert Price: $63.23
High Price: $76.06
Results: 20% in 68 Days

Past results are not indicative of future profits. This table is accurate, though not every trade is represented.

jb-vertical


Trading Lessons

Mainstream Financial News

Archives

Sell Dexcom For a 20% Win

April 16, 2017: Sell Dexcom for a 20% win in 68 days and congrats if you made money on the trade.

March 24, 2017: DexCom is pleased to announce that the U.S. Centers for Medicare & Medicaid Services (CMS) has published an article clarifying criteria for coverage and coding of the Dexcom G5 Mobile (Read More….)

Sell Cancer Genetics For an Awesome 133% Win!

April 16, 2017: Sell Cancer Genetics for an incredible 133% win in 85 days and congratulations if you made money on the trade.

December 9, 2016: H.C. Wainwright/ Rodman & Renshaw reiterates a Buy rating on Cancer Genetics, and sets a price target of $6.

December 7, 2016: Cancer Genetics announced a collaboration with BeiGene, (Read More….)

Sell Portola Pharmaceuticals For a 45% Win!

April 10, 2017: Sell Portola Pharmaceuticals for a 45% win and congratulations if you made money on the trade.

December 27, 2016: Portola Pharmaceuticals price target raised to $29 from $20 at Credit Suisse, reiterates Neutral rating.

December 26, 2016: Biotechnology firm Portola Pharmaceuticals had revenue of $12.1 million in 2015. For 2016, revenue is (Read More….)

Citigroup Names Medtronic As New Top Pick

April 07, 2017: Citigroup names Medtronic as their new Top Pick. Citigroup also reiterates their Buy rating on the stock. Citigroup says semi-annual survey of 40 US endocrinologists has come back significantly more positive for MDT, with: (1) big share gain expectations for both the pumps and CGM segments, and (2) positive read-through for ability (Read More….)

Novartis AG Drama Builds As It Keeps JULIET Results Secret For Now

February 28, 2016: Novartis announced that the FDA has approved Afinitor for the treatment of some tumors. The FDA has approved everolimus (Afinitor) for the treatment of adult patients with progressive, well-differentiated non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease. The approval was based on demonstration of improvement in progression-free survival (PFS) in a multicenter, randomized (2:1), placebo-controlled trial of everolimus 10 mg orally once daily plus best supportive care (BSC) to placebo plus BSC. (Read More….)

Opko Receives FDA Orphan Drug Status For Oligonucleotide

March 22, 2017: OPKO Pharmaceuticals LLC, a subsidiary of OPKO Health, Inc. announces that the Company has received orphan drug designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development for OPKO’s oligonucleotide-based AntagoNAT (CUR-1916) for the treatment of Dravet Syndrome. Currently, there is no approved treatment for Dravet Syndrome in (Read More….)

Jazz Pharmaceuticals Announces Positive Results From Phase 3 TONES 3 and TONES 4

March 20, 2017: Jazz Pharmaceuticals announced positive efficacy results from two global multicenter studies in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA). JZP-110 demonstrated highly statistically significant differences in the co-primary efficacy endpoints in the TONES 3 study at the 300 mg, 150 mg, 75 mg and 37.5 mg dose arms (Read More….)

Teligent FDA Approves Clobetasol Propionate Gel

March 8, 2017: Teligent announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Clobetasol Propionate Gel, 0.05%. This is Teligent’s second approval for 2017, and its thirteenth approval from its internally-developed pipeline of topical generic pharmaceutical medicines.

Based on recent QuintilesIMS Health (Read More….)

Ionis Pharmaceuticals Crushes Earnings and Revenue Estimates

February 28, 2017: Ionis Pharmaceuticals reports Q4 EPS of +$0.21 (GAAP) versus the -$0.20 estimate. Revenue also beat coming in at $160.3 million versus the $82 million estimate.

CEO Stanley T Crooke said, “In 2017, we expect to be breakeven or profitable at the operating line on a pro forma basis, driven in part (Read More….)

Ocular Therapeutix Rising Money Flow After Resubmits NDA for Dextenza

February 12, 2017: Biotechnology firm Ocular Therapeutix’s stock is surging higher on rising money flow after the company announced on January 23, 2017, that it had resubmitted an NDA for Dextenza. Ocular Therapeutix announced on January 23, 2017, that it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) (Read More….)

Sell ACADIA Pharmaceuticals for a 15.8% Win

February 11, 2017: Selling ACADIA Pharmaceuticals Monday for about a 15.8% win. Congratulations if you were able to make money on the trade.

February 5, 2017: ACADIA Pharmaceuticals Inc reportedly receives takeover approach from AstraZeneca according to an article on StreetInsider. Source: http://www.streetinsider.com/Hot+M+and+A/ACADIA+%28ACAD%29+Said+to+Receive+Takeover+Offer+from+AstraZeneca+%28AZN%29+-+Source/12496195.html

Pfizer may also have interest in acquiring lead drug candidate Nuplazid but (Read More….)

Zimmer Biomet Announces International Release of the Innovative Subchondroplasty Procedure

February 07, 2017: Zimmer Biomet announced today the international release of the Subchondroplasty (SCP) Procedure. The Company received CE Mark approval for the commercialization of its SCP Procedure to facilitate distribution in the European Union (EU) and other countries that recognize the CE Mark. Zimmer Biomet also received approval for distribution in Canada, Singapore, Malaysia (Read More….)

Cellectis Gets Investigational New Drug Approval From FDA For Phase 1 Trials With UCART123

February 6, 2017: Cellectis announced that it has received an Investigational New Drug approval from the FDA to conduct Phase 1 clinical trials with UCART123, the Company’s most advanced, wholly owned TALEN gene-edited product candidate, in patients with acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). This marks the first allogeneic, “off-the-shelf” (Read More….)

Lannett Beats On Earnings and Revenue

February 01, 2017: Lannett Company reports Q2 EPS of $0.92 versus the $0.83 estimate. Revenue also beat coming in at $170.9 million versus the $169 million estimate.

The CEO said, “Higher sales across a number of products and the addition of KU’s operations were key drivers to the 35% increase in our fiscal 2017 (Read More….)

Regeneron Pharmaceuticals Gets Approval of Kevzara With Sanofi For Rheumatoid Arthritis

February 1, 2017: Regeneron Pharmaceuticals, Inc. and Sanofi today announced that Health Canada approved Kevzara™ (sarilumab), an interleukin-6 (IL-6) receptor antibody, for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more biologic or non-biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

Kevzara (Read More….)

Ironwood Pharmaceuticals Reports Positive Top-Line Results from Phase III Linaclotide Trial

January 29, 2017: Astellas Pharma and Ironwood Pharmaceuticals announced today top-line results indicating that the Phase III clinical trial of linaclotide conducted in Japan in adults with chronic constipation (CC) met its primary endpoint.

Linaclotide is approved in Japan as the first prescription treatment for adults with irritable bowel syndrome with constipation (IBS-C). Linaclotide is (Read More….)

Top Performing Stocks On GuerillaStockTrading For Week Ending January 27 2017

OREX continues to be our dominant stock pick up a whopping +80% since profiled on GuerillaStockTrading.com

The biggest new gainer this last week was PLX which rocketed higher after it received FDA Orphan Drug Designation for CTP-656 for the treatment of Cystic Fibrosis.

Another big climber was CGIX after it launched its entry into comprehensive (Read More….)

Aratana Therapeutics Transiting From R&D To Revenue Producing Company

January 27, 2017: Aratana Therapeutics hot stock tip sent in through GuerillaStockTrading website. The catalyst is that with four FDA approvals for dogs, the company is transitioning from an R&D company to a revenue producing company this year. Thank you for sending in this hot stock tip with the catalyst.

January 24, 2017: Elanco Animal (Read More….)

Jefferies Reiterates TherapeuticsMD As Top Small-cap Pick For 2017

January 25, 2017: Jefferies reiterates TherapeuticsMD with a Buy rating and a price target of $18. Jefferies says that the investor tour of local compounding pharmacy provided unique insights into ‘001 market opportunity and reinforced our view that the bioidentical E+P VMS market is at a minimum 5.1M scrips or $714-$893M in sales (assumes 100% (Read More….)

Horizon Pharma Guides On Track To Deliver $2 Billion In Sales by 2020

January 10, 2017: In a JPM slide presentation, Horizon Pharma says it’s on track to deliver $2 billion in total net sales by 2020.

December 22, 2016: Horizon Pharma announces that it has received a Notice of Allowance from the United States Patent and Trademark Office for U.S. patent application number 13/610,580, entitled “Methods of (Read More….)

Novo Nordisk Marketing Authorization Granted by European Commission For Fiasp

January 10, 2017: Novo Nordisk A/S B announces marketing authorization granted by European Commission for Fiasp for treatment of diabetes in adults. Novo Nordisk expects to launch Fiasp in the first European countries in the first half of 2017. The authorisation covers all 28 European Union member states.

Fiasp is the brand name for fast-acting (Read More….)

PTC Therapeutics Breaks Above 200 MA On Positive CHMP Opinion

January 9, 2017: Biotechnology firm PTC Therapeutics’ stock broke above the 200 day MA today as it received notification from the European Commission (EC) of its adoption of a positive decision granting annual renewal of the conditional marketing authorization for Translarna (ataluren). The positive decision is based on the recent renewal recommendation by the Committee (Read More….)

CTI BioPharma FDA Hold Removed and Positive PERSIST-2 Phase 3 Data

January 7, 2017: Biotechnology firm CTI BioPharma announced on January 4, 2017 that the full clinical hold (February 2016) implemented by the U.S. Food and Drug Administration (FDA) on all clinical trials conducted under the Investigational New Drug (IND) application for pacritinib has now been removed. The Company’s complete response submission included, among other items, (Read More….)